升薏燮理合剂对荷瘤小鼠的NK细胞活性、白细胞介素2反应性影响的实验研究

作者	单位
钱彦方	海军总医院
李炳文	海军总医院
黄晋生	海军总医院
赵慧玲	海军总医院
黄友章	海军总医院
康静波	海军总医院

摘要点击次数: 1226

全文下载次数: 1216

中文摘要:

目的：探讨升薏燮理合剂对癌瘤的作用机理。方法：本研究采用中药升薏燮理合剂不同剂量及协同放、化疗对荷瘤小鼠进行药理实验。结果：本合剂可提高荷瘤小鼠自然杀伤细胞（ＮＫ细胞）的杀伤活性［空白对照组５２．７０±６．０１（％），中药小剂量组：５９．０１±１０．００（％），中药大剂量组：７８．３３±１０．９０（％），中药大剂量组与空白对照组比较有显著性差异，Ｐ＜０．０１］；化疗可抑制ＮＫ细胞的杀伤活性，而化疗加中药小剂量组可消除其毒副作用，提高杀伤活性（Ｐ＜０．０５），放疗各组也显示同样结果。中药合剂组可显著提高癌瘤小鼠淋巴细胞对白细胞介素２（ＩＬ－２）的反应性（Ｐ＜０．０５）；单用化疗虽可提高其反应性，但无显著性差异，单用中药后见其反应性有明显增长趋势。结论：本合剂可加强癌瘤小鼠的免疫机能，加强机体消除癌肿的敏感性，并可降低放、化疗的毒副作用。

英文摘要:

Objective: To explore therapeutic mechanism of Shengyi Xieli Mixture (SYXLM) on malignant tumor. Method: Chemotherapy, radiotherapy and different doses of SYXLM were used to treat tumor rats. Results: SYXLM could enhance the nature killer (NK) cell activities of the tumor rats, and this effect was dose dependent (control group 52. 70±6. 01, SYXLM No. 1 group 59. 01 ±10. 00,SYXLM No. 2 group 78. 33±10. 90, P<0. 01). The NK cell activities of the tumor rats were inhibited in the chemotherapy group alone, but they were enhanced in the group of chemotherapy combined with SYXLM (P<0. 05), the results were the same in the radiotherapy group alone and the group of radiotherapy combined with SYXLM (P<0. 05). The response of lymphocyte of the tumor ratS to IL-2 was enhanced significantly in SYXLM group compared with the control group. This response was enhanced insignificantly in the group in which radiotherapy combined with the SYXLM.Conclusion: The SYXLM could enhance the function of immune system of the tumor rats and diminish or reduce the side effect of radiotherapy, chemotherapy to the immune system of the tumor rats.

关闭